JUNS (Jupiter Neurosciences) Marketable Securities: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

JUNS Jupiter Neurosciences Inc JUNS
4 GF Score
Price $0.10
! 6 Warning Signs
View Full Analysis

What is Jupiter Neurosciences Marketable Securities?

Jupiter Neurosciences JUNS -8.09% 4 Marketable Securities is $0.00 Mil as of Mar. 2026. GuruFocus rates JUNS with a GF Score™ of 4/100. The stock has 6 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Jupiter Neurosciences's Marketable Securities for the quarter that ended in Mar. 2026 was $0.00 Mil.

Jupiter Neurosciences  (NAS:JUNS) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Jupiter Neurosciences Marketable Securities Related Terms

Jupiter Neurosciences Marketable Securities Historical Data

* Premium members only.

The historical data trend for Jupiter Neurosciences's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jupiter Neurosciences Marketable Securities Chart

Jupiter Neurosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Jupiter Neurosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
JUNS
4GF Score
Jupiter Neurosciences Inc JUNS
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jupiter Neurosciences Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $0.00 Mil mean?
Jupiter Neurosciences (JUNS) has a Marketable Securities of $0.00 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Jupiter Neurosciences and its competitors.
Is Jupiter Neurosciences' Marketable Securities too high?
Jupiter Neurosciences' current Marketable Securities is $0.00 Mil. Overall, Jupiter Neurosciences has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Jupiter Neurosciences' Marketable Securities compare to CLGN and RNAZ?
Jupiter Neurosciences' Marketable Securities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Jupiter Neurosciences and its competitors. Jupiter Neurosciences's current Marketable Securities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jupiter Neurosciences stock overvalued right now?
Jupiter Neurosciences (JUNS) has a current Marketable Securities of $0.00 Mil. The current Marketable Securities is $0.00 Mil. Jupiter Neurosciences' overall GF Score™ is 4/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Jupiter Neurosciences (JUNS), the current Marketable Securities is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jupiter Neurosciences Business Description

Address 1001 North US Highway 1, Suite 504, Jupiter, FL, USA, 33477
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
4GF Score

Get the complete analysis for JUNS

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.10
Price